AERI
Income statement / Annual
Last year (2021), Aerie Pharmaceuticals, Inc.'s total revenue was $194.13 M,
an increase of 133.51% from the previous year.
In 2021, Aerie Pharmaceuticals, Inc.'s net income was -$74.81 M.
See Aerie Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
| Period Ended |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
12/31/2012 |
| Operating Revenue |
$194.13 M
|
$83.14 M
|
$69.89 M
|
$24.18 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$26.85 M |
$25.33 M |
$4.83 M |
$641,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$167.29 M |
$57.81 M |
$65.06 M |
$23.54 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0.86 |
0.7 |
0.93 |
0.97 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$75.84 M
|
$74.01 M
|
$91.38 M
|
$86.12 M
|
$72.08 M
|
$52.39 M
|
$44.45 M
|
$29.87 M
|
$11.88 M
|
$9.27 M
|
| General & Administrative
Expenses |
$0.00
|
$137.18 M
|
$138.40 M
|
$120.61 M
|
$73.62 M
|
$44.48 M
|
$30.64 M
|
$20.10 M
|
$10.29 M
|
$5.02 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$137.81 M
|
$137.18 M
|
$138.40 M
|
$120.61 M
|
$73.62 M
|
$44.48 M
|
$30.64 M
|
$20.10 M
|
$10.29 M
|
$5.02 M
|
| Other Expenses |
$0.00 |
$2.30 M |
$22.77 M |
$26.55 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$213.64 M |
$213.50 M |
$252.55 M |
$233.28 M |
$145.69 M |
$96.87 M |
$75.09 M |
$49.97 M |
$22.17 M |
$14.29 M |
| Cost And Expenses |
$240.49 M |
$238.83 M |
$257.38 M |
$233.92 M |
$145.69 M |
$96.87 M |
$75.09 M |
$49.97 M |
$22.17 M |
$14.29 M |
| Interest Income |
$139,000.00 |
$1.98 M |
$2.97 M |
$3.43 M |
$1.75 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$28.90 M |
$26.48 M |
$15.26 M |
$2.53 M |
$2.37 M |
$2.54 M |
$2.49 M |
$628,000.00 |
$3.80 M |
$75,000.00 |
| Depreciation &
Amortization |
$37.50 M
|
$34.16 M
|
$18.11 M
|
$2.44 M
|
$1.41 M
|
$970,000.00
|
$252,000.00
|
$73,000.00
|
$64,000.00
|
$138,000.00
|
| EBITDA |
-$7.81 M
|
-$117.22 M
|
-$166.30 M
|
-$227.59 M
|
-$143.09 M
|
-$95.36 M
|
-$71.48 M
|
-$47.43 M
|
-$27.29 M
|
-$14.77 M
|
| EBITDA Ratio |
-0.04 |
-1.41 |
-2.38 |
-9.41 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
-0.23
|
-1.87
|
-2.68
|
-8.67
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$28.90 M
|
-$22.17 M
|
-$12.18 M
|
-$22.82 M
|
-$1.17 M
|
-$1.99 M
|
$862,000.00
|
$1.84 M
|
-$8.98 M
|
-$685,000.00
|
| Income Before Tax |
-$74.22 M |
-$177.86 M |
-$199.67 M |
-$232.57 M |
-$146.86 M |
-$98.87 M |
-$74.22 M |
-$48.13 M |
-$31.15 M |
-$14.98 M |
| Income Before Tax Ratio
|
-0.38
|
-2.14
|
-2.86
|
-9.62
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$593,000.00 |
$5.25 M |
-$90,000.00 |
$3,000.00 |
-$1.76 M |
$193,000.00 |
$139,000.00 |
$2.47 M |
-$5.18 M |
-$610,000.00 |
| Net Income |
-$74.81 M |
-$183.10 M |
-$199.58 M |
-$232.57 M |
-$145.11 M |
-$99.06 M |
-$74.36 M |
-$48.13 M |
-$31.15 M |
-$14.98 M |
| Net Income Ratio |
-0.39 |
-2.2 |
-2.86 |
-9.62 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-1.61 |
-3.99 |
-4.39 |
-5.58 |
-4.11 |
-3.4 |
-2.88 |
-2 |
-6.29 |
-0.95 |
| EPS Diluted |
-1.61 |
-3.99 |
-4.39 |
-5.58 |
-4.11 |
-3.4 |
-2.88 |
-2 |
-6.29 |
-0.95 |
| Weighted Average Shares
Out |
$46.34 M
|
$45.90 M
|
$45.43 M
|
$41.66 M
|
$35.32 M
|
$29.14 M
|
$25.78 M
|
$24.09 M
|
$4.96 M
|
$15.83 M
|
| Weighted Average Shares
Out Diluted |
$46.34 M
|
$45.90 M
|
$45.43 M
|
$41.66 M
|
$35.32 M
|
$29.14 M
|
$25.78 M
|
$24.09 M
|
$4.96 M
|
$15.83 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
